These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24884516)

  • 1. Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer.
    Zhang H; Ren Y; Pang D; Liu C
    World J Surg Oncol; 2014 May; 12():142. PubMed ID: 24884516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of stem cell protein Piwil2 and piR-932 in breast cancer.
    Zhang H; Ren Y; Xu H; Pang D; Duan C; Liu C
    Surg Oncol; 2013 Dec; 22(4):217-23. PubMed ID: 23992744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of AGBL2 on cell proliferation and chemotherapy resistance of gastric cancer.
    Zhu H; Zheng Z; Zhang J; Liu X; Liu Y; Yang W; Liu Y; Zhang T; Zhao Y; Liu Y; Su X; Gu X
    Hepatogastroenterology; 2015; 62(138):497-502. PubMed ID: 25916089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer.
    Xu D; Xu H; Ren Y; Liu C; Wang X; Zhang H; Lu P
    PLoS One; 2012; 7(10):e46670. PubMed ID: 23056395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
    DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
    Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients.
    Wang D; Lu P; Zhang H; Luo M; Zhang X; Wei X; Gao J; Zhao Z; Liu C
    Oncotarget; 2014 Nov; 5(21):10803-15. PubMed ID: 25301732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
    Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
    Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
    Park SY; Kim MJ; Park SA; Kim JS; Min KN; Kim DK; Lim W; Nam JS; Sheen YY
    Oncotarget; 2015 Nov; 6(35):37526-43. PubMed ID: 26462028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcription factors associated with epithelial-mesenchymal transition and cancer stem cells in the tumor centre and margin of invasive breast cancer.
    Alkatout I; Wiedermann M; Bauer M; Wenners A; Jonat W; Klapper W
    Exp Mol Pathol; 2013 Feb; 94(1):168-73. PubMed ID: 22985790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
    Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
    Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytoplasmic expression of aquaporin-1 in breast cancer cells and its relationship with clinicopathological characteristics and prognosis].
    Zhang B; Liu FF; Ma YJ; Gu F
    Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):904-9. PubMed ID: 24506959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
    Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
    Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression.
    Li L; Liu C; Amato RJ; Chang JT; Du G; Li W
    Oncotarget; 2014 Nov; 5(21):10840-53. PubMed ID: 25333262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
    Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of vacuole membrane protein 1 and its prognostic value in invasive ductal carcinoma of the breast].
    Liu F; Niu Y; Liu N; Zhang W; Wang SL; Liu H; Zhang TX
    Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):86-9. PubMed ID: 23710913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
    Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
    Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
    Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel biomarker C6orf106 promotes the malignant progression of breast cancer.
    Jiang G; Zhang X; Zhang Y; Wang L; Fan C; Xu H; Miao Y; Wang E
    Tumour Biol; 2015 Sep; 36(10):7881-9. PubMed ID: 25953261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.